The market for 10 billion diabetes is back on the ups and downs, and another variety is over-evaluated

As of September 18, CDE received 2360 consistent evaluation numbers (543 varieties of 609 enterprises, according to supplementary applications, the same between 2), of which 686 have been evaluated.
in the last week (September 11 to September 18), a total of 5 varieties (5 product rules) passed the consistent evaluation, and 3 product rules for the second evaluation, 2 product rules for the first home through.
is worth noting that Hangzhou Sino-American East China Pharmaceuticals' Pyrethyl glycodone tablets have been over-evaluated, or let the 10 billion diabetes market re-start, bringing new competitive pressure.
as the only insulin increaser on the market, one-way competition manufacturers.
and pyridoxine tablets are a compound of pyridoxine and metformin for the treatment of type 2 diabetes.
medical evidence shows that the two drug mechanisms complement each other to improve insulin sensitivity, effectively reduce sugar while positively regulating blood lipids, improve patients' blood pressure, reduce cardiovascular risk, and bring multiple benefits of treatment.
the current product only Jiangsu Deyuan Pharmaceuticals, Hangzhou Sino-American East China Pharmaceutical two enterprises have production code, the former has been with the first home on August 10 through a consistent evaluation.
so far, both companies have passed a consistent evaluation, meaning a new round of competition will begin.
2019, the overall sales of sample hospitals in China were about 90.16 million yuan, according to CPA data from the Chinese Pharmaceutical Society.
2020 Mid-Year Report released by East China Pharmaceuticals showed that the company achieved operating income of RMB16,661 million in the first half of the year, down 8.70% YoY, and net profit attributable to shareholders of listed companies was RMB1,731 million, up 8.45% YoY.
, the company's pharmaceutical industry sector achieved double growth against the trend, with first-half operating income of RMB6,084 million, up 6.69% YoY, and net profit of RMB1,378 million, up 5.00% YoY.
can be seen from the report, the company's diabetes key potential varieties of pyridine metformin tablets and cardiovascular key potential varieties of pyridoxine tablets sales in the first half of this year have doubled.
said on its interactive platform in May that pyridoxone metformin is the company's fastest growing second-tier diabetes line, achieving sales of more than 300 million yuan in 2019 and a promising impact of 800 million yuan in 2020.
company focus on the promotion of the product, the product into the 2019 edition of the national health insurance catalog, for its future expansion of sales scale and enhance market share will play an important role in strengthening the company in the field of diabetes treatment bigger and stronger established strategy and core competitiveness, the formation of the field of advantages of product clusters, but also to a certain extent to alleviate the future market competition pressure of a capo sugar tablets.
And Deyuan Pharmaceuticals' pyridoxine metformin tablets (15 mg/500 mg) (furidium) for the domestic first through a consistent evaluation of the pyridoxine tablets, but also the first in the country through a consistent evaluation of the compound sugar-lowering varieties.
In order to better guide the clinical rational drug use, as early as 2017, Deyuan Pharmaceuticals, together with domestic experts based on evidence-based medical evidence, put forward the "Expert Recommendations for clinical application of pyridoxine metformin compound preparations", for different patients to give professional drug guidance.
Pharmaceuticals is an emerging, modern pharmaceutical company focused on endocrinology, cardiovascular therapeutic drugs research and development, production, sales and after-sales service.
recent years, the company has responded positively to the call of the national generic drug quality and efficacy evaluation, and put into the consistent evaluation work.
the current German source pharmaceutical industry in the sale of endocrine, cardiovascular treatment drugs have been carried out consistent evaluation related work, and there are a number of varieties of evaluation.
the endocrine field, including four varieties, including furui, for the domestic first home evaluation.
This variety has been widely concerned since its development, after evaluation is expected to provide a reliable guarantee for clinical treatment, promote the single-chip compound preparation in the field of sugar reduction more widely used, for the vast number of patients to bring more benefits of treatment.